top of page

The Difference Between MDMA and Classic Psychedelics

MDMA vs. Classic Psychedelics: Different Mechanisms of Action

MDMA (3,4-methylenedioxymethamphetamine) and classic psychedelics (such as LSD, psilocybin, and mescaline) are both psychoactive substances that have been shown to have therapeutic potential. However, they work in different ways in the brain.


MDMA

MDMA is a serotonin-releasing agent, meaning that it increases the levels of serotonin in the brain. Serotonin is a neurotransmitter that plays a role in mood, emotion, and social behavior. MDMA also inhibits the reuptake of serotonin, dopamine, and norepinephrine, which further increases the levels of these neurotransmitters in the brain.

The increased levels of serotonin, dopamine, and norepinephrine in the brain are thought to be responsible for the euphoric, empathogenic, and prosocial effects of MDMA.


Classic Psychedelics

Classic psychedelics are agonists of serotonin 2A receptors. This means that they bind to and activate serotonin 2A receptors. Serotonin 2A receptors are found throughout the brain, but they are particularly concentrated in the visual cortex, hippocampus, and amygdala.

The activation of serotonin 2A receptors is thought to be responsible for the psychedelic effects of classic psychedelics, such as altered perception, thought patterns, and emotions.


Differences in Mechanism of Action

The main difference between the mechanism of action of MDMA and classic psychedelics is that MDMA increases the levels of serotonin in the brain, while classic psychedelics activate serotonin 2A receptors.


Another difference is that MDMA has a more pronounced effect on mood and emotion, while classic psychedelics have a more pronounced effect on perception and thought patterns.


Additionally, there is some data that there are increases in global connectivity and functional connectivity in the brain both during and after the psychedelic trip with the classic psychedelics, most notably Psilocybin and LSD. There is a correlation between the magnitude of global connectivity and level of improvement in anxiety or depression and the therapeutic outcome.


Clinical Applications

Both MDMA and classic psychedelics are being investigated for their potential therapeutic applications. MDMA is currently in Phase 3 clinical trials for the treatment of post-traumatic stress disorder (PTSD). Classic psychedelics are also being investigated for the treatment of a variety of mental health conditions, including depression, anxiety, and addiction.


Conclusion

MDMA and classic psychedelics work in different ways in the brain, but they both have potential therapeutic applications. MDMA is currently in Phase 3 clinical trials for the treatment of PTSD, and classic psychedelics are being investigated for the treatment of a variety of mental health conditions.


It is important to note that more research is needed to fully understand the mechanisms of action of MDMA and classic psychedelics, as well as their long-term safety and efficacy.

4 views0 comments

Comments


bottom of page